HALO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $24,404,236.69

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

^$82.27

▼ -0.27 (-0.33%)

As of 08/3/2026 04:00 PM ET

Days: 30 | 90 | 365

Halozyme Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2026	Helen Torley	CEO	Sell	1,923	$79.77	$153,397.71	767,780
7/1/2026	Bernadette Connaughton	Director	Sell	1,625	$76.71	$124,653.75	42,044
6/29/2026	Mahesh Krishnan	Director	Sell	7,304	$75.00	$547,800.00	14,462
6/3/2026	Helen Torley	CEO	Sell	10,000	$69.07	$690,700.00	767,780
6/1/2026	Bernadette Connaughton	Director	Sell	1,625	$66.21	$107,591.25	43,669
6/1/2026	Helen Torley	CEO	Sell	20,000	$67.58	$1,351,600.00	767,780
5/13/2026	Helen Torley	CEO	Sell	10,000	$69.19	$691,900.00	767,780
5/12/2026	Helen Torley	CEO	Sell	20,000	$71.75	$1,435,000.00	767,780
5/1/2026	Bernadette Connaughton	Director	Sell	1,625	$63.48	$103,155.00	38,498
4/6/2026	Helen Torley	CEO	Sell	10,000	$63.50	$635,000.00	767,780
4/2/2026	Helen Torley	CEO	Sell	20,000	$64.24	$1,284,800.00	767,780
3/10/2026	Cortney Caudill	COO	Sell	8,857	$67.64	$599,087.48	7,055
3/9/2026	Cortney Caudill	COO	Sell	20,000	$67.80	$1,356,000.00	14,366
3/4/2026	Helen Torley	CEO	Sell	10,000	$70.21	$702,100.00	767,780
3/2/2026	Helen Torley	CEO	Sell	20,000	$69.69	$1,393,800.00	767,780
2/5/2026	Helen Torley	CEO	Sell	10,000	$78.64	$786,400.00	708,719
2/3/2026	Helen Torley	CEO	Sell	20,000	$76.12	$1,522,400.00	708,719
1/5/2026	Bernadette Connaughton	Director	Sell	2,000	$70.25	$140,500.00	40,123
12/1/2025	Bernadette Connaughton	Director	Sell	829	$71.60	$59,356.40	42,123
12/1/2025	Helen Torley	CEO	Sell	16,569	$68.92	$1,141,935.48	708,719
11/11/2025	Helen Torley	CEO	Sell	20,000	$69.13	$1,382,600.00	733,719
11/10/2025	Bernadette Connaughton	Director	Sell	2,000	$68.48	$136,960.00	42,952
11/1/2025	Cortney Caudill	COO	Sell	4,263	$65.19	$277,904.97	12,737
10/3/2025	Helen Torley	CEO	Sell	20,000	$69.03	$1,380,600.00	733,719
10/1/2025	Bernadette Connaughton	Director	Sell	2,000	$75.24	$150,480.00	44,952
10/1/2025	Helen Torley	CEO	Sell	20,000	$75.35	$1,507,000.00	733,719
9/22/2025	Nicole Labrosse	CFO	Sell	2,227	$77.95	$173,594.65	22,079
9/10/2025	Nicole Labrosse	CFO	Sell	20,000	$75.71	$1,514,200.00	24,306
9/3/2025	Helen Torley	CEO	Sell	20,000	$74.44	$1,488,800.00	733,719
9/2/2025	Bernadette Connaughton	Director	Sell	4,000	$73.68	$294,720.00	46,952
8/12/2025	Helen Torley	CEO	Sell	20,000	$63.51	$1,270,200.00	733,719
7/9/2025	Helen Torley	CEO	Sell	20,000	$56.43	$1,128,600.00	733,719
6/24/2025	Helen Torley	CEO	Sell	20,000	$53.73	$1,074,600.00	733,719
6/20/2025	Helen Torley	CEO	Sell	20,000	$52.96	$1,059,200.00	733,719
4/28/2025	Jeffrey William Henderson	Director	Sell	4,497	$60.37	$271,483.89	28,611
4/1/2025	Jeffrey William Henderson	Director	Sell	503	$64.05	$32,217.15	33,108
3/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$58.69	$293,450.00	33,611
2/27/2025	Michael J. LaBarre	SVP	Sell	1,697	$58.28	$98,901.16	173,756
2/25/2025	Michael J. LaBarre	SVP	Sell	10,000	$58.05	$580,500.00	185,453
2/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$56.30	$281,500.00	38,611
1/6/2025	Jeffrey William Henderson	Director	Sell	10,000	$50.01	$500,100.00	43,611
10/16/2024	Michael J. LaBarre	SVP	Sell	10,000	$53.26	$532,600.00	173,756
10/9/2024	Helen Torley	CEO	Sell	10,000	$52.58	$525,800.00	676,744
9/25/2024	Helen Torley	CEO	Sell	10,000	$56.34	$563,400.00	676,744
9/18/2024	Michael J. LaBarre	SVP	Sell	10,000	$62.03	$620,300.00	173,756
9/12/2024	Helen Torley	CEO	Sell	10,000	$59.20	$592,000.00	676,744
9/10/2024	Helen Torley	CEO	Sell	10,000	$59.09	$590,900.00	676,744
8/21/2024	Michael J. LaBarre	SVP	Sell	10,000	$61.75	$617,500.00	168,176
8/14/2024	Matthew L. Posard	Director	Sell	9,881	$57.70	$570,133.70	69,874
8/12/2024	Matthew L. Posard	Director	Sell	10,000	$55.72	$557,200.00	89,755
7/24/2024	Michael J. LaBarre	SVP	Sell	10,000	$55.12	$551,200.00	168,176
7/22/2024	Nicole Labrosse	CFO	Sell	5,000	$53.93	$269,650.00	15,480
6/27/2024	Nicole Labrosse	CFO	Sell	10,000	$51.93	$519,300.00	15,480
6/11/2024	Matthew L. Posard	Director	Sell	10,000	$50.01	$500,100.00	109,755
5/22/2024	Michael J. LaBarre	SVP	Sell	10,000	$45.38	$453,800.00	168,176
4/17/2024	Michael J. LaBarre	SVP	Sell	10,000	$38.49	$384,900.00	168,176
3/12/2024	Michael J. LaBarre	SVP	Sell	10,000	$41.64	$416,400.00	156,558
2/28/2024	Michael J. LaBarre	SVP	Sell	10,000	$39.55	$395,500.00	156,558
12/12/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.63	$396,300.00	151,911
10/17/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.52	$365,200.00	151,911
9/19/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.10	$391,000.00	151,911
8/31/2023	Helen Torley	CEO	Sell	10,000	$42.82	$428,200.00	623,666
8/29/2023	Helen Torley	CEO	Sell	10,000	$42.40	$424,000.00	623,666
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/17/2023	Helen Torley	CEO	Sell	10,000	$43.18	$431,800.00	623,666
8/14/2023	James M. Daly	Director	Sell	10,000	$43.74	$437,400.00	20,503
8/11/2023	James M. Daly	Director	Sell	10,000	$43.71	$437,100.00	30,503

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

97.79% of Halozyme Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/10/2026	Wedge Capital Management L L P NC	403,824	$31.61M	0.5%	N/A	0.340%
7/10/2026	Tema ETFs LLC	32,598	$2.55M	0.1%	+0.6%	0.027%
7/10/2026	Handelsbanken Fonder AB	631,899	$49.46M	0.1%	+28.1%	0.533%
7/10/2026	Redhawk Wealth Advisors Inc.	29,690	$2.32M	0.2%	-9.6%	0.025%
7/9/2026	Focus Financial Network Inc.	3,651	$0.29M	0.0%	+6.7%	0.003%
7/9/2026	Oliver Luxxe Assets LLC	33,014	$2.58M	0.4%	-34.2%	0.028%
7/8/2026	Gradient Investments LLC	16,437	$1.29M	0.0%	N/A	0.014%
7/8/2026	Assenagon Asset Management S.A.	997,643	$78.09M	0.1%	+4,578.9%	0.841%
7/7/2026	Balefire LLC	2,936	$0.23M	0.0%	N/A	0.002%
7/7/2026	GAMMA Investing LLC	4,487	$0.35M	0.0%	+13.7%	0.004%
7/7/2026	Harbor Investment Advisory LLC	1,494	$0.12M	0.0%	N/A	0.001%
7/7/2026	Cooper Investors PTY Ltd.	55,023	$4.31M	2.0%	N/A	0.046%
7/2/2026	Versant Capital Management Inc	1,693	$0.13M	0.0%	+37.3%	0.001%
7/2/2026	Collective Family Office LLC	8,113	$0.64M	0.1%	+14.2%	0.007%
6/18/2026	Western Wealth Management LLC	3,545	$0.23M	0.0%	N/A	0.003%
6/18/2026	Pacer Advisors Inc.	295,524	$19.10M	0.0%	-68.5%	0.249%
6/3/2026	NewEdge Advisors LLC	4,933	$0.32M	0.0%	-57.4%	0.004%
5/27/2026	Alpine Woods Capital Investors LLC	4,351	$0.28M	0.1%	N/A	0.004%
5/26/2026	Glenmede Trust Co. NA	146,717	$9.48M	0.0%	+22.4%	0.124%
5/22/2026	Segall Bryant & Hamill LLC	298,056	$19.26M	0.2%	-3.0%	0.251%
5/21/2026	Argent Capital Management LLC	9,054	$0.59M	0.0%	+52.2%	0.008%
5/21/2026	BankChampaign National Association	3,531	$0.23M	0.2%	N/A	0.003%
5/19/2026	Western Wealth Management LLC	3,545	$0.23M	0.0%	N/A	0.003%
5/19/2026	Edgestream Partners L.P.	51,124	$3.30M	0.1%	-52.2%	0.043%
5/19/2026	Janus Henderson Group PLC	1,233,658	$79.74M	0.0%	+42.8%	1.040%
5/19/2026	Centaurus Financial Inc.	23,174	$1.50M	0.1%	+3.1%	0.020%
5/19/2026	Arkadios Wealth Advisors	19,622	$1.27M	0.0%	-4.2%	0.017%
5/19/2026	Smith Group Asset Management LLC	4,930	$0.32M	0.0%	-39.2%	0.004%
5/18/2026	Amundi	121,599	$7.86M	0.0%	+503.5%	0.103%
5/18/2026	California State Teachers Retirement System	136,346	$8.81M	0.0%	+22.9%	0.115%
5/18/2026	Empowered Funds LLC	384,538	$24.85M	0.2%	-24.7%	0.324%
5/16/2026	The Manufacturers Life Insurance Company	157,805	$10.20M	0.0%	-1.2%	0.133%
5/16/2026	Infrastructure Capital Advisors LLC	8,434	$0.55M	0.0%	+15.5%	0.007%
5/16/2026	Quantinno Capital Management LP	138,547	$8.95M	0.0%	+4.2%	0.117%
5/16/2026	SummitTX Capital L.P.	13,550	$0.88M	0.0%	N/A	0.011%
5/15/2026	Corsair Capital Management L.P.	10,000	$0.65M	0.1%	N/A	0.008%
5/15/2026	OMERS ADMINISTRATION Corp	73,789	$4.77M	0.0%	+47.3%	0.062%
5/15/2026	Vivaldi Capital Management LP	24,499	$1.58M	0.2%	-11.5%	0.021%
5/15/2026	Epoch Investment Partners Inc.	1,138,377	$73.57M	0.4%	+113.4%	0.960%
5/14/2026	Renaissance Technologies LLC	731,811	$47.30M	0.1%	+30.1%	0.617%
5/14/2026	Gabelli Funds LLC	46,200	$2.99M	0.0%	-56.3%	0.039%
5/14/2026	Public Employees Retirement System of Ohio	37,245	$2.41M	0.0%	-2.5%	0.031%
5/14/2026	Arrowstreet Capital Limited Partnership	1,918,149	$123.97M	0.1%	-40.5%	1.619%
5/14/2026	Inceptionr LLC	11,923	$0.77M	0.2%	N/A	0.010%
5/14/2026	Mizuho Markets Americas LLC	1,323,544	$85.54M	2.3%	+4.3%	1.117%
5/14/2026	Bank of Nova Scotia	5,049	$0.33M	0.0%	-8.7%	0.004%
5/14/2026	Gibbs Wealth Management	9,049	$0.59M	0.1%	+191.8%	0.008%
5/14/2026	Sei Investments Co.	457,783	$29.59M	0.0%	-49.2%	0.386%
5/13/2026	First Citizens Bank & Trust Co.	9,088	$0.59M	0.0%	+2.0%	0.008%
5/13/2026	First Trust Advisors LP	1,482,340	$95.80M	0.1%	+46.5%	1.251%
5/8/2026	PNC Financial Services Group Inc.	11,860	$0.77M	0.0%	+16.0%	0.010%
5/8/2026	Convergence Investment Partners LLC	37,599	$2.43M	0.4%	+21.9%	0.032%
5/7/2026	Dimensional Fund Advisors LP	2,079,827	$134.40M	0.0%	-1.2%	1.756%
5/7/2026	AlphaCentric Advisors LLC	4,794	$0.31M	0.3%	+5.8%	0.004%
5/7/2026	SEB Asset Management AB	34,700	$2.24M	0.0%	N/A	0.029%
5/7/2026	Swiss National Bank	232,700	$15.04M	0.0%	+0.9%	0.196%
5/7/2026	Precision Wealth Strategies LLC	7,234	$0.47M	0.2%	+5.8%	0.006%
5/6/2026	Aurora Investment Counsel	18,452	$1.19M	0.7%	-26.3%	0.016%
5/6/2026	California Public Employees Retirement System	260,961	$16.87M	0.0%	+9.9%	0.220%
5/6/2026	Future Fund LLC	95,121	$6.15M	2.2%	+14.6%	0.080%
5/6/2026	Assetmark Inc.	166,617	$10.77M	0.0%	+21.3%	0.141%
5/6/2026	Gallacher Capital Management LLC	8,614	$0.56M	0.2%	+33.6%	0.007%
5/6/2026	Financiere des Professionnels Fonds d investissement inc.	14,374	$0.93M	0.1%	+9.2%	0.012%
5/6/2026	Bessemer Group Inc.	539	$35K	0.0%	-23.2%	0.000%
5/6/2026	Allspring Global Investments Holdings LLC	15,357	$1M	0.0%	-48.7%	0.013%
5/6/2026	Independent Financial Group LLC	3,170	$0.21M	0.0%	N/A	0.003%
5/5/2026	Twin Capital Management Inc.	11,422	$0.74M	0.1%	+1.4%	0.010%
5/5/2026	Illinois Municipal Retirement Fund	90,977	$5.88M	0.1%	+50.5%	0.077%
5/5/2026	Pacific Wealth Management	5,401	$0.35M	0.2%	N/A	0.005%
5/5/2026	Livforsakringsbolaget Skandia Omsesidigt	116,100	$7.50M	0.3%	+10.7%	0.098%
5/5/2026	Sanctuary Advisors LLC	12,907	$0.83M	0.0%	-56.2%	0.011%
5/5/2026	Sigma Planning Corp	20,592	$1.33M	0.0%	+114.7%	0.017%
5/5/2026	Hillsdale Investment Management Inc.	110,050	$7.11M	0.2%	+2.4%	0.093%
5/4/2026	State of Michigan Retirement System	28,338	$1.83M	0.0%	+1.8%	0.024%
5/4/2026	Principal Financial Group Inc.	264,490	$17.09M	0.0%	+4.9%	0.223%
5/4/2026	Arbejdsmarkedets Tillaegspension	408,391	$26.39M	0.7%	+8.6%	0.345%
5/2/2026	Diversify Wealth Management LLC	31,504	$1.99M	0.0%	+49.1%	0.027%
5/1/2026	Citizens Financial Group Inc. RI	25,822	$1.67M	0.0%	N/A	0.022%
5/1/2026	Fifth Third Bancorp	68,128	$4.40M	0.0%	+4,206.4%	0.058%
5/1/2026	Candriam S.C.A.	31,075	$2.01M	0.0%	-77.0%	0.026%
4/30/2026	Hsbc Holdings PLC	28,781	$1.85M	0.0%	-65.0%	0.024%
4/30/2026	Bernzott Capital Advisors	68,277	$4.41M	2.1%	+0.7%	0.058%
4/30/2026	Graetz Wealth LLC	3,568	$0.23M	0.2%	N/A	0.003%
4/30/2026	First Horizon Corp	1,045	$68K	0.0%	-14.6%	0.001%
4/30/2026	Kestra Advisory Services LLC	9,620	$0.62M	0.0%	-17.8%	0.008%
4/30/2026	Azzad Asset Management Inc. ADV	11,884	$0.77M	0.1%	-2.0%	0.010%
4/30/2026	Granite Investment Partners LLC	51,719	$3.34M	0.2%	+76.5%	0.044%
4/30/2026	Sumitomo Mitsui Trust Group Inc.	10,800	$0.70M	0.0%	+27.1%	0.009%
4/30/2026	Isthmus Partners LLC	5,971	$0.39M	0.0%	-11.2%	0.005%
4/30/2026	Oregon Public Employees Retirement Fund	24,062	$1.56M	0.0%	+2.6%	0.020%
4/29/2026	Koa Wealth Management LLC	93,822	$6.06M	4.4%	+0.8%	0.079%
4/29/2026	Unified Investment Management	21,319	$1.38M	1.4%	-1.4%	0.018%
4/29/2026	Swedbank AB	160,712	$10.39M	0.0%	-0.8%	0.136%
4/29/2026	Shelton Wealth Management LLC	18,032	$1.17M	0.5%	-15.0%	0.015%
4/28/2026	Hodges Capital Management Inc.	134,696	$8.71M	0.7%	+18.8%	0.114%
4/28/2026	California First Leasing Corp	30,300	$1.96M	0.6%	N/A	0.026%
4/28/2026	Marietta Investment Partners LLC	49,042	$3.17M	0.6%	+38.9%	0.041%
4/28/2026	Stephens Investment Management Group LLC	1,218,668	$78.76M	1.1%	-0.4%	1.029%
4/28/2026	Praxis Investment Management Inc.	4,391	$0.28M	0.0%	-14.1%	0.004%
4/28/2026	QRG Capital Management Inc.	5,964	$0.39M	0.0%	-4.6%	0.005%

Data available starting January 2016

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $82.27

$82.11

$83.62

50 Day Range

MA: $74.80

$66.28

$83.44

52 Week Range

Now: $82.27

$58.67

$84.44

Volume

1,367,654 shs

Average Volume

1,784,528 shs

Market Capitalization

$9.76 billion

P/E Ratio

29.59

Dividend Yield

N/A

Beta

0.85

Who are the company insiders with the largest holdings of Halozyme Therapeutics?: Halozyme Therapeutics' top insider shareholders include:
Randal J Kirk (Major Shareholder)
Helen Torley (CEO)
Kathryn Falberg (Director)
Kenneth J Kelley (Director)
Robert Engler (Director)
Connie Matsui (Director)
Michael J Labarre (SVP)
John Stuart Patton (Director)
Matthew L Posard (Director)
Jeffrey William Henderson (Director)
Learn More about top insider investors at Halozyme Therapeutics.
Who are the major institutional investors of Halozyme Therapeutics?: Halozyme Therapeutics' top institutional investors include:
Assenagon Asset Management S.A. — 0.84%
Handelsbanken Fonder AB — 0.53%
Wedge Capital Management L L P NC — 0.34%
Cooper Investors PTY Ltd. — 0.05%
Oliver Luxxe Assets LLC — 0.03%
Tema ETFs LLC — 0.03%
Learn More about top institutional investors of Halozyme Therapeutics stock.
Which major investors are selling Halozyme Therapeutics stock?: Within the last quarter, HALO stock was sold by these institutional investors:
Oliver Luxxe Assets LLC
Redhawk Wealth Advisors Inc.
In the last year, company insiders that have sold Halozyme Therapeutics company stock include:
Helen Torley (CEO)
Bernadette Connaughton (Director)
Nicole Labrosse (CFO)
Mahesh Krishnan (Director)
Cortney Caudill (COO)
Learn More investors selling Halozyme Therapeutics stock.
Which major investors are buying Halozyme Therapeutics stock?: Within the last quarter, HALO stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Wedge Capital Management L L P NC
Handelsbanken Fonder AB
Cooper Investors PTY Ltd.
Gradient Investments LLC
Balefire LLC
Harbor Investment Advisory LLC
Collective Family Office LLC